<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546855</url>
  </required_header>
  <id_info>
    <org_study_id>AHTH-101</org_study_id>
    <nct_id>NCT03546855</nct_id>
  </id_info>
  <brief_title>Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.</brief_title>
  <official_title>Clinical Study of Apatinib Mesylate in the Treatment of Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anhui Provincial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced&#xD;
      Cervical Cancer After Radiotherapy and First-line Chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive apatinib treatment until disease progression or intolerable&#xD;
      toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apatinib treating patients with advanced cervical cancer after radiotherapy and first-line chemotherapy.</measure>
    <time_frame>12 week</time_frame>
    <description>The time from the beginning of treatment to observing the progression of the disease or the death of any cause.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg/d po.28d as one cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg/d po,28 days as one cycle</description>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cervical cancer confirmed by pathology;&#xD;
&#xD;
          2. At least one measuring lesion (RECIST 1.1) or ascites (B ultrasound);&#xD;
&#xD;
          3. Recurrence after the treatment of pelvic radiotherapy and first-line chemotherapy;&#xD;
&#xD;
          4. Baseline blood routine and biochemical indicators meet the following criteria:&#xD;
&#xD;
             ① ANC ≥ 1.5 × 109 / L;&#xD;
&#xD;
               -  HB ≥ 90g / L;&#xD;
&#xD;
                    -  PLT ≥ 100 × 109 / L; ④ ALB≥30g / L;&#xD;
&#xD;
                         -  TBIL≤1.5 times the upper limit of normal (ULN); ⑥ ALT and AST&lt;2 × ULN;&#xD;
                            ⑦ Plasma Cr&lt;1.5 × ULN&#xD;
&#xD;
          5. no blood transfusion , blood products, g-csf and other hematopoietic stimulation&#xD;
             factors were used in 14 days ;&#xD;
&#xD;
          6. The expected survival time is longer than 3 months;&#xD;
&#xD;
          7. The pregnancy test (serum or urine)should be carried out for women in childbearing age&#xD;
             before 7 days into the group and the results were negative, and willing to use&#xD;
             appropriate methods of contraception during the test and after 8 weeks out of group&#xD;
&#xD;
          8. The subjects volunteered to participate in this study, signed informed consent,&#xD;
             followed up with good compliance and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergies to apatinib and/or its excipients&#xD;
&#xD;
          2. People with high blood pressure and antihypertensive drug treatment can not drop to&#xD;
             normal range (systolic blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg),&#xD;
             with level-1 above coronary heart disease, arrhythmia over class I (including QTc&#xD;
             lengthened men &gt; 450 ms, women &gt; 470 ms).&#xD;
&#xD;
          3. According to NYHA standard, Ⅲ ~ Ⅳ cardiac insufficiency, or LVEF &lt; 50%;&#xD;
&#xD;
          4. Various factors that affect oral drugs (such as inability to swallow, nausea,&#xD;
             vomiting, chronic diarrhea, intestinal obstruction, etc.);&#xD;
&#xD;
          5. Patients with a clear tendency of gastrointestinal bleeding, including the following&#xD;
             situations: local active ulcer lesions, and fecal occult blood (++); Patients with&#xD;
             black stool and hematemesis in 2 months;&#xD;
&#xD;
          6. Abnormal coagulation function (INR&gt;1.5, APTT&gt;1.5 ULN), with bleeding&#xD;
             tendency;Hereditary or acquired bleeding and thrombosis tendencies (such as&#xD;
             hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.);&#xD;
&#xD;
          7. Long-term unhealed wounds or fractures; Major surgery or severe traumatic injury,&#xD;
             fracture or ulcer in 4 weeks;&#xD;
&#xD;
          8. With abdominal fistula, gastrointestinal perforation or abdominal abscess;Active&#xD;
             patients with HBVor HCV;&#xD;
&#xD;
          9. Active brain metastases, meningitis, cancer patients with spinal cord compression, CT&#xD;
             or MRI examination revealed brain or soft meningeal disease (21 days before the drug&#xD;
             treatment; the symptoms of patients with brain metastases from stable can into the&#xD;
             group, but need to be confirmed by the cerebral MRI, CT or vein imaging evaluation for&#xD;
             no symptoms in cerebral hemorrhage).&#xD;
&#xD;
         10. CT or MRI showed that the tumor lesion was less than 5 mm away from the large vessel,&#xD;
             or the lesion invaded local large vessels;&#xD;
&#xD;
         11. Pregnant or lactating women;&#xD;
&#xD;
         12. Patients with a history of psychotropic substance abuse or have mental disorders;&#xD;
&#xD;
         13. According to the researchers' judgment, patients who have serious harm to the&#xD;
             patient's safety or affect the patients for completing the research;&#xD;
&#xD;
         14. Subjects considered inappropriate by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

